Paolo Tarantino: Phase 3 EVER-002 trial is out

Paolo Tarantino shared an article by Binghe Xu on X:

“Phase 3 EVER-002 trial (also known as TROPics02 in Asian patients) out in Nature Medicine.

Consistent with TROPics, SG improved PFS & OS over chemotherapy in HR+/HER2- MBC, with a small PFS delta but with a meaningful OS delta (~5 mo).

Same OS benefit irrespective of Trop2 experiment.”

Tittle: Sacituzumab govitecan in HR+HER2− metastatic breast cancer: the randomized phase 3 EVER-132-002 trial

Authors: Binghe Xu, Shusen Wang, Min Yan, Joohyuk Sohn, Wei Li, Jinhai Tang, Xiaojia Wang, Ying Wang, Seock-Ah Im, Dongdong Jiang, Theresa Valdez, Anandaroop Dasgupta, Yiran Zhang, Yilin Yan, Kimberly M. Komatsubara, Wei-Pang Chung, Fei Ma and Ming-Shen Dai 

Source: Paolo Tarantino/LinkedIn

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.